As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected
individuals, their families and caregivers, and healthcare systems. Although AD can be …

Dementia with Lewy bodies (DLB) is clinically defined by the presence of visual
hallucinations, fluctuations, rapid eye movement (REM) sleep behavioral disorder, and …

Background Increasing evidence supports the use of plasma biomarkers of
neurodegeneration and neuroinflammation to screen and diagnose patients with dementia …

Early identification of cognitive impairment in Parkinson's disease (PD) has important clinical
and research implications. The aim of our study was to investigate the role of plasma tau …

Background Blood phosphorylated tau (p-tau) forms are promising Alzheimer's disease (AD)
biomarkers, but validation in matrices other than ethylenediaminetetraacetic acid (EDTA) …

Introduction Despite the clinical implementation, there remain significant gaps in our
knowledge regarding the impact of race/ethnicity or common medical comorbidity on plasma …

Several advances in fluid and tissue-based biomarkers for use in Parkinson's disease (PD)
and other synucleinopathies have been made in the last several years. While work …

Concomitant Alzheimer's disease (AD) pathology is a frequent event in the context of Lewy
body disease (LBD), occurring in approximately half of all cases. Evidence shows that LBD …

Introduction The prognostic role of plasma neurofilament light chain (NfL), phospho-tau, beta-
amyloid, and GFAP is still debated in Parkinson's disease (PD). Methods Plasma p-tau181 …

Clinical trials in dementia with Lewy bodies: the evolving c... : Current Opinion in Neurology
Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient …